Videos

Västra Hamnen Möter

Västra Hamnen Möter - Clemondo Group

Västra Hamnen Möter - Inwido

Västra Hamnen Möter - Nexam Chemical Holding

Västra Hamnen Möter - Advenica

Västra Hamnen Möter - OptiCept Technologies

Västra Hamnen Möter - Safeture

Västra Hamnen Möter - SenzaGen

Västra Hamnen Möter - Xintela

Västra Hamnen Möter - Arrow Lake

Västra Hamnen Möter - Spago Nanomedical

Västra Hamnen Möter - BPC Instruments

Västra Hamnen Möter - Shape Robotics

Västra Hamnen Möter - Neola Medical

Västra Hamnen Möter - Nasdaq

Västra Hamnen Möter - Precise Biometrics

Medimi presents Q4 2024

Västra Hamnen Möter - Tobias Schildfat

Nyheter

Crunchfish presents Q4 2024

Crunchfish's CEO on the new approach

Crunchfish comments on Q1 2025

Västra Hamnen Corporate Finance initierar bevakning av Precise Biometrics

Västra Hamnen Möter - Charlotta Falvin

Medimi presenterar Q4 2024

Crunchfish om Q4 2024

Crunchfish comments on Q3 2025

Västra Hamnen Möter - Percy Nilsson

Västra Hamnen Corporate Finance initierar bevakning av Gabather

aXichem on aXivite's market opportunities

Västra Hamnen Corporate Finance initierar bevakning av Advenica

Bioextrax presenterar Q3 2025 

Bioextrax presenterar Q2 2025 

Västra Hamnen Möter - Greg Dingizian

Västra Hamnen Corporate Finance initierar bevakning av USWE

Crunchfishs vd om den nya approachen

Västra Hamnen M&A - Tilläggsköpeskilling

Västra Hamnen M&A - Buddagen

News

Västra Hamnen Möter - Minesto

Interview with Precise Biometrics

Crunchfish kommenterar Q1 2025

Precise Biometrics about Q1 2025

Crunchfish kommenterar Q3 2025

Precise Biometrics about Q2 2025

Västra Hamnen M&A - Earnouts

Västra Hamnen Möter - I Love Lund

Slutförda uppdrag

Västra Hamnen Möter - Clemondo

Västra Hamnen Meets

Västra Hamnen Möter - 4C Strategies

Precise Biometrics about Q3 2025

Västra Hamnen Meets - Neola Medical

Bioextrax presents Q2 2025

Västra Hamnen M&A - the bidding day

Västra Hamnen M&A - UDI with Fram Advokatbyrå

Västra Hamnen Meets - Nexam Chemical Holding

Västra Hamnen Meets- BPC Instruments

Bioextrax presents Q3 2025

Västra Hamnen Meets - OptiCept Technologies

Västra Hamnen Meets - SenzaGen

Västra Hamnen Möter - Lyckegård Group

Intervju med Precise Biometrics om Q3 2025

Västra Hamnen Meets - Spago Nanomedical

Västra Hamnen Möter - Mellby Gård

Västra Hamnen Meets - Clemondo

Västra Hamnen M&A - Due Diligence

Företrädesemission - Crunchfish 2024

Västra Hamnen Meets - Safeture

Intervju med Precise Biometrics vd 

Västra Hamnen Meets - Tobias Schildfat

Västra Hamnen Möter - Trelleborg

Västra Hamnen Möter - Jim Roslund

Crunchfish comments on Q2 2025

Precise Biometrics om Q12025

Västra Hamnen Möter - Örjan Johansson

Västra Hamnen Meets - Gasporox

Gabather comments on Q2 2025

Precise Biometrics om Q2 2025

Västra Hamnen Möter - Windon Energy Group

Västra Hamnen Möter - Bengt Kjell

Riktad emission - Crunchfish 2025

Crunchfish kommenterar Q2 2025

Services

Transactions

About us

Contact

Here is more information about Västra Hamnen Corporate Finance's services.

Here you will find information about Västra Hamnen Corporate Finance's ongoing and completed transactions.

Here you will find more information about Västra Hamnen Corporate Finance.

Here, Västra Hamnen Corporate Finance's information for investors is gathered.

Investor relations

Västra Hamnen Corporate Finance

Market focus about Nilsson Special Vehicles

Lipum reported in its Q2 report that the manufacturing process of SOL-116 is nearing the final phase. The drug candidate is now being produced according to GMP standards, and the last batch is underway. At the same time, some of the company's major shareholders have provided short-term loans to finance the activities for the rest of the year. Shortly, we expect Lipum to announce a plan for financing the upcoming phase II study, which we now expect to start in Q2 2026.

Lipum: Merging with Flerie

Lipum: Finding financial support

The clinical study report of Lipum’s phase I study with SOL-116 was published in April. In line with the topline data, the complete findings strongly support further clinical development of the drug candidate. The company is now planning the phase II study in rheumatoid arthritis (RA), expected to start in Q1 2026. Essential for the development is securing the funding. By the end of Q1, Lipum’s cash holdings amounted to MSEK 4.26. We anticipate a rights issue being announced shortly.

Lipum: Focus on financing phase II

Just before the release of the year-end report, Lipum announced positive topline results from its phase I study with SOL-116 in rheumatoid arthritis. Now, the company is busy planning for the next clinical step, expected to start in Q1 2026. Financing, completing production of the drug candidate, study planning and filing the application are among the activities on the company’s agenda in 2025. Lipum is in transition to become a phase II company, which is an inflection point in terms of valuation. Until Lipum has reached some of its milestones, we keep our tight risk-adjustment, implying a fair value of SEK 15.83 per share.

Lipum: A busy year ahead

During the third quarter, Lipum reported continued advancement in the clinical program with SOL-116. The last patient in the phase I study was included, the final report is expected to be completed in Q1 2025. In parallel, CEO Ola Sandborgh confirms that the production collaboration with NorthX Biologics is proceeding according to plan and that Lipum's new CMO Dr. Peter Hovstadius is in place. We have updated our interest rate assumptions in the model, which has led to a new fair value of SEK 15.19 (10.81) per share.

Lipum: Progress towards the next phase

In Lipum’s Q2 report, CEO Ola Sandborgh repeated that he expects to complete the phase I study with SOL-116 during the second half of  2024

Lipum: On track for completing phase I

Chronic inflammation, such as rheumatoid arthritis, affects millions of people globally.

Lipum: A new approach to chronic inflammation

Martin Dominique

Tobias Karlsson

Lipum

Lipum

Analysts

Martin Dominique

Tobias Karlsson

Initial analysis

Lipum: A new approach to chronic inflammation

Research updates

Related Videos